Centrally Acting ACE Inhibition in SLE
A Novel Phase 2 Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy of Centrally Acting, Non-toxic ACE Inhibition in Cognitive Impairment Associated With SLE
Sponsor: Lupus Research Alliance
Listed as NCT04486118, this PHASE2 trial focuses on Systemic Lupus Erythematosus and remains ongoing. Sponsored by Lupus Research Alliance, it has been updated 14 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Oct 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 9 earlier versions
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2023 — Mar 2024 [monthly]
Recruiting PHASE2
-
Jan 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jan 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Lupus Research Alliance
- Northwell Health
For direct contact, visit the study record on ClinicalTrials.gov .